Tumour specific regulation of telomerase RNA gene expression visualized by in situ hybridization.
Maintenance of telomere structure by the ribonucleoprotein enzyme telomerase is considered central to the development of most human cancers. However, regulatory mechanisms governing telomerase expression during oncogenesis are largely unknown. We address potential tumour-specific regulation of telomerase RNA gene expression by RNA in situ hybridization to over 300 tumour samples of germ cell and epithelial origin. Twenty-six per cent of non-small cell lung cancers (NSCLC), expressed detectable levels of the telomerase RNA gene (hTR), and interestingly expression was almost confined to squamous carcinomas (41%), being rare in pulmonary adenocarcinomas and large-cell anaplastic carcinomas (P=0.006). Low frequency hTR expression was also associated with adenocarcinoma of the breast (13%), and ovary (17%). In comparison, hTR expression was detected in 43% of cervical cancers with no significant differences in frequency between squamous-cell carcinoma and adenocarcinoma or in transitions between intraepithelial neoplasia and invasive carcinoma. In contrast to the common epithelial cancers, the malignant cells in 73% of testicular germ-cell tumours (seminomas and teratomas), expressed hTR consistent with hTR expression in normal testicular germ cells. Differentiated tissues within ovarian germ cell tumours and in testicular teratomas lacked detectable hTR expression. These studies show that different tumour types have distinct patterns of hTR expression, which has implications for our understanding of mechanisms regulating telomerase activity and for targeting the telomerase RNA component as an anti-cancer therapy.
Soder
A I
AI
CRC Department of Medical Oncology, University of Glasgow, CRC Beatson Laboratories, Bearsden, UK.
Going
J J
JJ
Kaye
S B
SB
Keith
W N
WN
D005260:Female; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D017403:In Situ Hybridization; D008297:Male; D009369:Neoplasms / Q000201:enzymology* / Q000235:genetics; D012334:RNA, Neoplasm / Q000235:genetics / Q000378:metabolism*; D012680:Sensitivity and Specificity; D019098:Telomerase / Q000096:biosynthesis*
D012334:RNA, Neoplasm; D019098:Telomerase